Press Releases

September 9, 2020
BOSTON , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common
August 6, 2020
— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials   — —  Enrolled first biliary atresia patients in second odevixibat pivotal study — —  Completed two financing transactions to secure cash into beginning of 2022 — —  Management to host conference call and webcast today at
July 30, 2020
BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will participate in a fireside chat presentation
July 30, 2020
—  Conference call and webcast to be held at 10:00 a.m. ET   —  BOSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call